Anthropic buys biotech startup for $400 million — with fewer than 10 employees

Anthropic acquired Coefficient Bio — a stealth biotech-AI startup that was only slightly over eight months old at the time of the deal. The acquisition cost more than $400 million and was completed entirely in Anthropic shares — with no cash component. For a company that itself has raised billions from Amazon, Google, and other investors to develop safe AI, this is a non-trivial move: using its own shares as currency to acquire another team, however tiny.

Coefficient Bio operated in stealth mode — with virtually no public presence and no disclosure of its developments. The team consists of fewer than ten people, and nearly all of them are former computational biology researchers from Genentech, one of the world's largest biopharmaceutical giants. This fact alone explains the price: Anthropic was not buying a finished product or specific technology, but a rare and difficult-to-replicate cluster of expertise at the intersection of deep learning and molecular biology.

Such specialists are few and far between on the open market. The acquired team will join Anthropic's healthcare and biological sciences division. This direction has existed within the company for some time, but very little is publicly known about it.

Anthropic traditionally prefers to act cautiously in medical areas — and for good reason: the cost of error in biomedicine is vastly higher than in consumer AI applications. The context of the deal matters. Computational biology is one of the areas where AI is already fundamentally changing the rules.

A few years ago, DeepMind's AlphaFold demonstrated that neural networks can predict three-dimensional protein structures more accurately and quickly than decades of traditional experimental research. Since then, the race has not stopped: large language models are being used to develop new drugs, analyze genomic data, diagnose diseases, and predict molecular interactions. Anthropic, possessing some of the most powerful foundational models in the industry, apparently decided that the moment for a serious move into biomedicine had arrived.

$400 million for eight months of work and a team of fewer than ten people — this is not simply a market anomaly. It is a clear indicator that specialists capable of combining real expertise in AI with deep understanding of biological systems have become one of the most scarce resources in the technology industry. The Genentech alumni are not theorists: they worked on real drugs that underwent clinical trials on living patients.

They understand the regulatory environment, grasp the limitations of experimental data, and from their own experience know how beautiful results on paper shatter against the complexity of the real world. It is precisely this applied intuition that is valued at hundreds of millions of dollars. The structure of the deal speaks for itself.

Payment exclusively in shares means that the Coefficient Bio team is making a long-term bet on the growth and value of Anthropic, while the company itself does not spend its cash reserves on the acquisition. For a startup that has already raised several billion dollars from major investors but is still operationally unprofitable, this is a rational way to build talent without burning liquidity. Taken together, this adds up to a clear trend: leading AI laboratories no longer limit themselves to creating universal general-purpose models.

They are methodically building vertical stacks — from foundational model to deep specialized expertise in a specific industry. Medicine and biology have become the next key frontier. The acquisition of Coefficient Bio is one of the first clear public signals that Anthropic intends to participate seriously in this race.